Disclosed are oxadiazole derivatives represented by general formula (I) such as -(5-{ 3-chloro-4-[( 1-methylethyl)oxy]phenyl} -1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydro-1H-2-benzazepine and [7-(5-{ 3-chloro-4-[(1-methylethyl)oxy]phenyl} -1,2,4-oxad iazol-3-yl )-1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl]acetic acid. The compounds of formula (I) are used to treat conditions or diseases mediated by S1P1 receptors such as multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependant diabetes.
